Because Patients Can’t WaitSM, BioNJ hosted its first ever Patient Advocacy Team Briefing with guest speakers from the Hypertrophic Cardiomyopathy Association, the National Alliance of Mental Illness and the Myelodysplastic Syndromes Foundation who shared their experiences with our Team.
Congratulations to BioNJ Members Elusys Therapeutics on the FDA approval of ANTHIM® (obiltoxaximab) injection, the company’s monoclonal antibody (mAb) anthrax antitoxin; Eli Lilly and Company on the approval of Taltz® (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis and Pfizer for the approval of XALKORI® (crizotinib) for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer. See more below.
BioNJ is working with New Jersey’s congressional delegation in the request for the Centers for Medicare and Medicaid Services to withdraw their proposed rule to test new Medicare Part B prescription drug models. Click here to read BioNJ President and CEO Debbie Hart’s statement.
On April 12-13, 2016, BIO will host the Legislative Day Fly-In, when biotechnology executives from across the country come to Washington D.C. for a day and a half of legislative briefings and advocacy. Participants will meet in small groups with congressional Members and senior staff to discuss important legislative issues facing the biotechnology industry.
A special call out to precious 7-year old Patient Advocate Max Schill who lobbied Congress for the passage of the 21st Century Cures legislation. BioNJ was honored to have “Magic” Max as part of this year’s BioNJ Annual Dinner Meeting where he received the Star Wars sneakers featured in Max’s most recent CuresNow photo. Max, may the force be with you.
Click here to read this week’s Weekender.